A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
Open Access
- 2 March 2023
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medical Research Methodology
- Vol. 23 (1), 1-12
- https://doi.org/10.1186/s12874-023-01867-y
Abstract
Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug–drug interactions, multidrug combinations often exhibit different toxicity profiles than those of single drugs, leading to a complex trial scenario. Numerous methods have been proposed for the design of phase I drug combination trials. For example, the two-dimensional Bayesian optimal interval design for combination drug (BOINcomb) is simple to implement and has desirable performance. However, in scenarios where the lowest and starting dose is close to being toxic, the BOINcomb design may tend to allocate more patients to overly toxic doses, and select an overly toxic dose combination as the maximum tolerated dose combination. To improve the performance of BOINcomb in the above extreme scenarios, we widen the range of variation of the boundaries by setting the self-shrinking dose escalation and de-escalation boundaries. We refer to the new design as adaptive shrinking Bayesian optimal interval design for combination drug (asBOINcomb). We conduct a simulation study to evaluate the performance of the proposed design using a real clinical trial example. Our simulation results show that asBOINcomb is more accurate and stable than BOINcomb, especially in some extreme scenarios. Specifically, in all ten scenarios, the percentage of correct selection is higher than the BOINcomb design within 30 to 60 patients. The proposed asBOINcomb design is transparent and simple to implement and can reduce the trial sample size while maintaining accuracy compared with the BOINcomb design.Keywords
This publication has 30 references indexed in Scilit:
- Dose-finding design for multi-drug combinationsClinical Trials, 2011
- Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challengesStatistics in Medicine, 2010
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic AgentsBiometrics, 2009
- Phase I Drug Combination Trial Design: Walking the TightropeJournal of Clinical Oncology, 2009
- Design Issues in Dose-Finding Phase I Trials for Combinations of Two AgentsJournal of Biopharmaceutical Statistics, 2009
- Bayesian Dose Finding in Oncology For Drug Combinations by Copula RegressionJournal of the Royal Statistical Society Series C: Applied Statistics, 2009
- Dose–schedule finding in phase I/II clinical trials using a Bayesian isotonic transformationStatistics in Medicine, 2008
- An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinationsStatistics in Medicine, 2006
- Two‐Dimensional Dose Finding in Discrete Dose SpaceBiometrics, 2005
- A non‐parametric approach to the design and analysis of two‐dimensional dose‐finding trialsStatistics in Medicine, 2004